Skin tags, moles, and the midlife skin changes that warrant attention

Midlife skin changes don't all belong in the same category. Some are genuinely benign and need only a record in your mind. Others are benign but signal something metabolic. A few warrant actual dermatologic evaluation rather than reassurance. Knowing which is which is what makes the difference between appropriate surveillance and missed diagnosis.

Skin tags — acrochordon is the clinical term — are soft, flesh-colored or slightly darker pedunculated growths that appear in skin folds and friction areas. They are not cancerous. But their appearance is not purely a cosmetic aging phenomenon. The research linking skin tags to insulin resistance and metabolic syndrome is consistent and underappreciated in routine clinical encounters. Skin tags correlate with fasting insulin levels, waist circumference, and other metabolic syndrome markers independently of age. The mechanism appears to involve insulin's role as a growth factor — elevated insulin signaling promotes keratinocyte and fibroblast proliferation in susceptible areas. This does not mean every person with a skin tag has metabolic syndrome; correlation is not equivalence. But if you have multiple new skin tags, particularly appearing in clusters in skin folds, and you haven't had your fasting insulin, fasting glucose, or HbA1c looked at recently, this is a reasonable prompt to do so. Skin tags as a cosmetic problem and skin tags as a metabolic signal are two different ways of seeing the same thing. Your provider may only be looking at them as the first.

Seborrheic keratoses are the rough, sometimes waxy, "stuck-on" looking benign growths that become common in midlife and beyond. They can be alarming in appearance — they often have irregular surfaces, varied color, and can grow to significant size — but they are essentially benign epithelial tumors with no malignant potential. Dermatologists sometimes call them the barnacles of aging, which is anatomically appropriate if aesthetically unfortunate. They can be removed for cosmetic reasons or if they become irritated or catchable on clothing, but they don't require monitoring for transformation. The one context in which seborrheic keratoses warrant attention is the sudden eruption of large numbers of new ones, called the Leser-Trelat sign — a rare paraneoplastic phenomenon occasionally associated with internal malignancy. This is genuinely rare and not a reason for alarm if you notice a few new keratoses; it's a reason for evaluation if you notice a sudden rapid explosion of many new ones.

Actinic keratoses are a different matter and are worth learning to recognize. These are rough, scaly patches — often on the face, scalp (in people with thin or no hair), backs of hands, and forearms — that represent precancerous changes from cumulative UV damage. They're not skin cancer yet. They're the cellular precursor: keratinocytes with atypia that haven't yet broken through the basement membrane. Dermatologists treat them because the annual rate of progression to squamous cell carcinoma is meaningful, particularly in people with many lesions. Actinic keratoses are the thing that bridges benign sun damage and actual skin cancer, which is why annual dermatologic examination matters — not because every rough patch needs intervention, but because distinguishing actinic keratosis from irritated seborrheic keratosis from early squamous cell requires eyes that have done this before, often alongside dermoscopy.

Mole changes are where the stakes are highest. The ABCDE criteria are a useful lay framework: Asymmetry (one half doesn't match the other), Border irregularity (jagged, notched, or blurred edges), Color variation (different shades of brown, black, red, white, or blue within one lesion), Diameter (greater than 6mm, though melanomas can be smaller), and Evolution (any change — in size, shape, color, or new symptoms like bleeding, itching, or crusting). No single criterion is a diagnosis; evolution is the most clinically important for existing lesions you're monitoring. A mole that has been stable for twenty years and remains stable is a different thing from a mole that has changed noticeably in the last six months. The second one warrants dermatology, not reassurance.

Basal cell carcinoma is the most common skin cancer and the one with the most favorable prognosis when caught at any early stage. It typically presents as a pearly or translucent bump, sometimes with visible blood vessels, sometimes as a flat scarlike lesion, most often in sun-exposed areas. It grows slowly and almost never metastasizes, but it can invade locally and cause substantial damage if untreated. Squamous cell carcinoma is the second most common, can metastasize (more rarely than melanoma, but it does happen), and often arises in areas of chronic sun damage or from actinic keratoses. Melanoma is less common than either but accounts for the large majority of skin cancer deaths because of its metastatic potential. It is also among the most treatable cancers when identified early — the five-year survival for stage I melanoma is above 95 percent; by stage IV that drops precipitously. The annual skin check is not just a dermatology billing opportunity. It's the surveillance that catches things at the stage where they're beatable.

The sun reactivity you may be noticing — burning more quickly than you used to, freckling more easily, a general sense that your skin is more sensitive to UV than it was at 30 — reflects the cumulative depletion of melanocyte function and the loss of some of the protective thickening that younger skin maintains. This is real, it means your risk of UV-induced damage is incrementally higher than it was, and it is an argument for taking sunscreen seriously in a way you perhaps didn't in your 20s. The evidence for daily broad-spectrum SPF 30 or higher in reducing actinic keratosis formation and squamous cell incidence is solid; the evidence for its role in melanoma reduction is somewhat more complicated but still directionally supportive.

Where peptide approaches may enter this picture is in the general context of skin support and cellular health, not in any capacity that replaces dermatologic evaluation for concerning lesions. GHK-Cu has been researched extensively in the context of skin repair and remodeling — it appears to upregulate collagen synthesis, support wound healing, and have some anti-inflammatory effects at the tissue level. Research on GHK-Cu for general skin quality is more developed than for most cosmetic peptides, and topical formulations are the most studied application. This is meaningfully different from any claim that a peptide approach substitutes for monitoring a changing mole or evaluating an actinic keratosis — those require dermatology, full stop. The cellular health angle of GHK-Cu is relevant as part of a broader skin maintenance approach; it's not a treatment for any lesion that warrants evaluation.

The metabolic work that may reduce skin tag formation — improving insulin sensitivity, addressing fasting glucose if it's trending upward, supporting weight management in ways that reduce visceral adiposity — is worth doing independent of the skin tags themselves. If the skin tags are signaling metabolic dysregulation, that dysregulation has consequences elsewhere in the body that matter more than the skin tags do.

The foundational interventions are concrete. Annual dermatologic skin checks, particularly from age 40 onward and earlier if you have a personal or family history of skin cancer, multiple atypical moles, or significant cumulative sun exposure. Daily sunscreen on exposed areas regardless of your plans for the day — UV exposure accumulates through windows, through incidental time outdoors, in ways that add up over decades. Metabolic evaluation if you have new multiple skin tags and haven't had your fasting insulin and glucose assessed. And a willingness to advocate for a full skin examination rather than accepting a brief visual scan and reassurance.

What midlife skin changes are signaling, collectively, is that the skin has been keeping a record — of sun exposure, of metabolic conditions, of time — and that record is now becoming legible. Most of it is benign. Some of it is worth acting on. The willingness to look carefully and bring in expertise for the parts that warrant it is what moves you from passive observation to informed surveillance.